Celcuity Inc. (CELC): Price and Financial Metrics
CELC Price/Volume Stats
|Current price||$9.40||52-week high||$14.40|
|Prev. close||$9.55||52-week low||$7.50|
|Day high||$9.74||Avg. volume||76,757|
|50-day MA||$9.83||Dividend yield||N/A|
|200-day MA||$10.51||Market Cap||207.65M|
CELC Stock Price Chart Interactive Chart >
Celcuity Inc. (CELC) Company Bio
Celcuity LLC, a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the response rates of cancer patients treated with targeted therapies in the United States. It develops CELx tests to diagnose breast, lung, colon, ovarian, kidney, bladder, and hematological cancers. The company was founded in 2012 and is based in Minneapolis, Minnesota.
CELC Latest News Stream
|Loading, please wait...|
CELC Latest Social Stream
View Full CELC Social Stream
Latest CELC News From Around the Web
Below are the latest news stories about CELCUITY INC that investors may wish to consider to help them evaluate CELC as an investment opportunity.
Explore the potential of the best short-squeeze stocks to buy now as companies attempt to prove pessimistic traders wrong.
Leading key opinion leaders to review the treatment landscape in breast and prostate cancer and the importance of targeting the PI3K/mTOR pathway in hormonally driven tumor typesDiscussion of the planned Phase 1b/2 trial for gedatolisib in combination with Nubeqa® (darolutamide) in patients with mCRPCEvent to be webcast from 10:00 a.m. – 12:00 p.m. ET on September 21, 2023 MINNEAPOLIS, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuin
Although the concept of short-squeeze stocks is one best left for speculators, these ideas have a touch of rationality behind them.
Celcuity Enters into a Clinical Trial Collaboration and Supply Agreement with Bayer to Provide Nubeqa® (darolutamide) for Planned Phase 1b/2 Clinical Trial
MINNEAPOLIS, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it has entered into a clinical trial collaboration and supply agreement with Bayer AG for Celcuity’s Phase 1b/2 clinical trial of gedatolisib and Nubeqa® (darolutamide) in patients with metastatic castration resistant prostate cancer (mCRPC). As part of the supply agreement, Bayer will provide Nubeqa to C
Celcuity Announces Plan to Conduct Phase 1b/2 Clinical Trial in Metastatic Castration Resistant Prostate Cancer
- Received FDA clearance of IND for gedatolisib in combination with darolutamide - Virtual Science Day to be held on September 21, 2023 from 10:00 a.m. – 12:00 p.m. ET MINNEAPOLIS, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, has been notified by the U.S. Food and Drug Administration (FDA) that its Investigational New Drug (IND) submission has been reviewed, and Celcuity can proceed
CELC Price Returns